PL1748791T3 - LOS IgtB Neisseria Meningitidis jako adjuvant - Google Patents

LOS IgtB Neisseria Meningitidis jako adjuvant

Info

Publication number: PL1748791T3
Authority: PL; Poland
Prior art keywords: los; adjuvant; igtb; neisseria meningitidis; tri
Prior art date: 2004-05-11

Application number

PL05745670T

Other languages

English (en)

Inventor

Liana Juliana Josephine Steeghs

De Winkel Johannes Gerardus Joseph Van

Der Ley Peter André Van

Original Assignee

De Staat Der Nederlanden Vert Door De Mini Van Vws

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-11

Filing date

2005-05-11

Publication date

2010-08-31

2005-05-11 Application filed by De Staat Der Nederlanden Vert Door De Mini Van Vws filed Critical De Staat Der Nederlanden Vert Door De Mini Van Vws

2010-08-31 Publication of PL1748791T3 publication Critical patent/PL1748791T3/pl

Links

239000002671 adjuvant Substances 0.000 title abstract 2
241000588650 Neisseria meningitidis Species 0.000 title 1
241001212279 Neisseriales Species 0.000 abstract 2
150000004043 trisaccharides Chemical class 0.000 abstract 2
108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 abstract 1
210000004443 dendritic cell Anatomy 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
150000002482 oligosaccharides Polymers 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Amplifiers (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Fats And Perfumes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Soft Magnetic Materials (AREA)
Steroid Compounds (AREA)

PL05745670T 2004-05-11 2005-05-11 LOS IgtB Neisseria Meningitidis jako adjuvant PL1748791T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04076401		2004-05-11
EP05745670A EP1748791B1 (en)	2004-05-11	2005-05-11	NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT
PCT/NL2005/000358 WO2005107798A1 (en)	2004-05-11	2005-05-11	NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT

Publications (1)

Publication Number	Publication Date
PL1748791T3 true PL1748791T3 (pl)	2010-08-31

Family

ID=34928212

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05745670T PL1748791T3 (pl)	2004-05-11	2005-05-11	LOS IgtB Neisseria Meningitidis jako adjuvant

Country Status (18)

Country	Link
US (1)	US20080138359A1 (pl)
EP (1)	EP1748791B1 (pl)
JP (1)	JP5174457B2 (pl)
KR (1)	KR101270838B1 (pl)
CN (1)	CN1997392B (pl)
AT (1)	ATE464066T1 (pl)
AU (1)	AU2005239963B2 (pl)
BR (1)	BRPI0511026C1 (pl)
CA (1)	CA2566409C (pl)
DE (1)	DE602005020608D1 (pl)
DK (1)	DK1748791T3 (pl)
ES (1)	ES2344114T3 (pl)
MX (1)	MXPA06013093A (pl)
NZ (1)	NZ551250A (pl)
PL (1)	PL1748791T3 (pl)
PT (1)	PT1748791E (pl)
SI (1)	SI1748791T1 (pl)
WO (1)	WO2005107798A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904581D0 (sv) *	1999-12-15	1999-12-15	A & Science Invest Ab	A novel helicobacter pylori-binding substance and use thereof
KR101515078B1 (ko)	2005-12-22	2015-04-24	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EP2476433A1 (en)	2006-03-30	2012-07-18	GlaxoSmithKline Biologicals S.A.	Immunogenic composition
CA2690708A1 (en)	2007-06-26	2008-12-31	Glaxosmithkline Biologicals S.A.	Vaccine
WO2009049013A2 (en) *	2007-10-09	2009-04-16	Tufts University	Cholera vaccines
UA99659C2 (uk) *	2008-05-30	2012-09-10	Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі	Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
WO2010130899A1 (fr) *	2009-05-14	2010-11-18	Sanofi Pasteur	Vaccin meningocoque a base de lipooligosaccharide (los) et de proteine de neisseria meningitidis
CA2761924C (fr)	2009-05-14	2017-10-31	Sanofi Pasteur	Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
MX2012011189A (es)	2010-03-26	2013-02-07	Glaxosmithkline Biolog Sa	Vacuna contra el virus e inmunodeficiencia humana.
JP2014501225A (ja)	2010-09-27	2014-01-20	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
KR20120068647A (ko) *	2010-12-18	2012-06-27	아이진 주식회사	개선된 면역반응을 유도하는 백신
JP6002763B2 (ja)	2011-07-07	2016-10-05	デスタートデルネダーランデン、フェルト．ドールデミニスターファンフェーウェーエス	グラム陰性細菌の外膜小胞を、洗浄剤を含まずに生産するためのプロセス
GB201310008D0 (en)	2013-06-05	2013-07-17	Glaxosmithkline Biolog Sa	Immunogenic composition for use in therapy
AU2015359503B2 (en)	2014-12-10	2019-05-09	Glaxosmithkline Biologicals Sa	Method of treatment
KR102002034B1 (ko)	2015-07-09	2019-07-22	에스에프씨주식회사	고효율과 장수명을 갖는 유기 발광 소자
US11292808B2 (en) *	2016-01-28	2022-04-05	Intravacc B.V.	Modified hexa-acylated neisserial LPS
EP3263695A1 (en)	2016-06-29	2018-01-03	GlaxoSmithKline Biologicals SA	Immunogenic compositions
US10918709B2 (en) *	2016-10-31	2021-02-16	Eyegene Inc.	Immune modulator and vaccine composition containing the same
US10973908B1 (en)	2020-05-14	2021-04-13	David Gordon Bermudes	Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en)	2020-07-22	2026-01-27	David Gordon Bermudes	Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9101359A (nl)	1991-08-07	1993-03-01	Nederlanden Staat	Nieuw saccharide-peptide-conjugaat, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk saccharide-peptide-conjugaat omvat.
AU762369B2 (en) *	1998-11-03	2003-06-26	De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur	LPS with reduced toxicity from genetically modified gram negative bacteria
GB0103170D0 (en) *	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
WO2003018054A1 (en) *	2001-08-31	2003-03-06	Chiron Srl.	Helicobacter pylori vaccination
US20060057160A1 (en)	2002-08-02	2006-03-16	Ralph Biemans	Vaccine composition
CA2654706A1 (en) *	2006-06-12	2007-12-21	Nathalie Devos	Neisseria meningitidis lipooligosaccharide vaccine

2005
- 2005-05-11 PL PL05745670T patent/PL1748791T3/pl unknown
- 2005-05-11 NZ NZ551250A patent/NZ551250A/en not_active IP Right Cessation
- 2005-05-11 WO PCT/NL2005/000358 patent/WO2005107798A1/en not_active Ceased
- 2005-05-11 PT PT05745670T patent/PT1748791E/pt unknown
- 2005-05-11 DE DE602005020608T patent/DE602005020608D1/de not_active Expired - Lifetime
- 2005-05-11 AU AU2005239963A patent/AU2005239963B2/en not_active Ceased
- 2005-05-11 MX MXPA06013093A patent/MXPA06013093A/es active IP Right Grant
- 2005-05-11 US US11/596,319 patent/US20080138359A1/en not_active Abandoned
- 2005-05-11 SI SI200531025T patent/SI1748791T1/sl unknown
- 2005-05-11 BR BRPI0511026A patent/BRPI0511026C1/pt not_active IP Right Cessation
- 2005-05-11 CA CA2566409A patent/CA2566409C/en not_active Expired - Fee Related
- 2005-05-11 AT AT05745670T patent/ATE464066T1/de active
- 2005-05-11 ES ES05745670T patent/ES2344114T3/es not_active Expired - Lifetime
- 2005-05-11 KR KR1020067026018A patent/KR101270838B1/ko not_active Expired - Fee Related
- 2005-05-11 CN CN2005800181701A patent/CN1997392B/zh not_active Expired - Fee Related
- 2005-05-11 EP EP05745670A patent/EP1748791B1/en not_active Expired - Lifetime
- 2005-05-11 JP JP2007513087A patent/JP5174457B2/ja not_active Expired - Fee Related
- 2005-05-11 DK DK05745670.9T patent/DK1748791T3/da active

Also Published As

Publication number	Publication date
BRPI0511026B1 (pt)	2019-01-08
EP1748791A1 (en)	2007-02-07
SI1748791T1 (sl)	2010-07-30
AU2005239963A1 (en)	2005-11-17
CA2566409A1 (en)	2005-11-17
CA2566409C (en)	2012-12-04
BRPI0511026B8 (pt)	2020-01-21
EP1748791B1 (en)	2010-04-14
ES2344114T3 (es)	2010-08-18
BRPI0511026C1 (pt)	2021-05-25
KR20070029742A (ko)	2007-03-14
DE602005020608D1 (de)	2010-05-27
US20080138359A1 (en)	2008-06-12
NZ551250A (en)	2010-03-26
PT1748791E (pt)	2010-07-15
BRPI0511026A (pt)	2007-11-27
JP2007537248A (ja)	2007-12-20
MXPA06013093A (es)	2007-08-08
ATE464066T1 (de)	2010-04-15
DK1748791T3 (da)	2010-06-28
JP5174457B2 (ja)	2013-04-03
WO2005107798A1 (en)	2005-11-17
AU2005239963B2 (en)	2011-01-06
CN1997392B (zh)	2011-06-01
CN1997392A (zh)	2007-07-11
KR101270838B1 (ko)	2013-07-04

Publication	Publication Date	Title
PL1748791T3 (pl)	2010-08-31	LOS IgtB Neisseria Meningitidis jako adjuvant
MX393384B (es)	2025-03-24	Adyuvantes sinteticos de glucopiranosil-lipido.
AU2457100A (en)	2000-09-14	Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2006012209A3 (en)	2007-03-22	A new adjuvant composition
WO2000062800A3 (en)	2001-01-11	Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
MX2010012999A (es)	2012-03-07	Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
NO20031646L (no)	2003-06-14	Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
SG170127A1 (en)	2011-04-29	Vaccine compositions comprising a saponin adjuvant
EP2433647A3 (en)	2012-06-06	GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
FR11C0001I2 (fr)	2017-05-19	Vaccins combines contre neisseria meningitidis
EP2279758A3 (en)	2012-03-14	Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
BRPI0409133A (pt)	2006-05-02	formulações farmacêuticas contendo metilnaltrexona
WO2004084950A3 (en)	2005-01-27	Cell targeting methods and compositions
EP2246067A3 (en)	2011-07-13	Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
TW200626132A (en)	2006-08-01	Topical nepafenac formulations
WO2009101475A3 (en)	2009-10-22	Use of glycosylceramides for enhancing the immune response to antigens
TW200613308A (en)	2006-05-01	Cyclobutanetetracarboxylate compound and preparation method thereof
WO2008140598A3 (en)	2016-06-09	Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
WO2005120564A3 (en)	2007-11-15	Vaccine compositions and methods
MXPA05008906A (es)	2005-10-05	Estra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.
MY127452A (en)	2006-12-29	Vaccines.
WO2003020237A3 (de)	2003-11-20	Kosmetische zubereitung
WO2004101737A3 (en)	2005-09-29	A novel adjuvant capable of specifically activating the adaptive immune response
HK1141793A (en)	2010-11-19	Cationic lipids compositions and methods for enhancing immune responses to vaccines
TH106356S (th)	2011-03-15	อุปกรณ์สอดใส่ในการปลูกถ่ายเนื้อเยื่อ